Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes

(2016) Romina Lomonaco et al.   DIABETES CARE

Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials

(2016) Henry Ginsberg et al.   DIABETES OBESITY & METABOLISM

Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

(2016) S. Mudaliar et al.   DIABETES OBESITY & METABOLISM

Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4

(2016) T. Blevins et al.   DIABETES OBESITY & METABOLISM

Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial

(2016) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3

(2016) R. M. Bergenstal et al.   DIABETES OBESITY & METABOLISM

A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1

(2016) S. Garg et al.   DIABETES OBESITY & METABOLISM

Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials

(2016) Julio Rosenstock et al.   DIABETES OBESITY & METABOLISM

Effect of Insulin Versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes

(2016) Ildiko Lingvay et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial

(2015) An Tang et al.   DIABETES CARE

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5

(2015) John B. Buse et al.   DIABETES CARE

Liver Fat Content and Hepatic Insulin Sensitivity in Overweight Patients With Type 1 Diabetes

(2015) Gemma Llauradó et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels

(2015) Paola Portillo-Sanchez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids

(2015) Daniel F. Vatner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

(2014) Yan Bi et al.   ACTA DIABETOLOGICA

Changes in Glucose and Fat Metabolism in Response to the Administration of a Hepato-Preferential Insulin Analog

(2014) Dale S. Edgerton et al.   DIABETES

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

(2014) Robert R. Henry et al.   DIABETES CARE

The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease

(2014) Maryann Maximos et al.   HEPATOLOGY

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects

(2014) Vikram P. Sinha et al.   JOURNAL OF CLINICAL PHARMACOLOGY

How to Avoid Being Surprised by Hepatotoxicity at the Final Stages of Drug Development and Approval

(2013) Arie Regev   Clinics in Liver Disease

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

(2013) M. C. Moore et al.   DIABETES

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus

(2013) V. P. Sinha et al.   DIABETES OBESITY & METABOLISM

Hepatoselectivity and the evolution of insulin

(2013) R. Herring et al.   DIABETES OBESITY & METABOLISM

Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD)

(2013) Ajay Duseja et al.   Hepatology International

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

(2012) J. Rosenstock et al.   DIABETES CARE

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications

(2012) Kenneth Cusi   GASTROENTEROLOGY

Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging

(2012) Arian Mashhood et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Insulin effects in muscle and adipose tissue

(2011) George Dimitriadis et al.   DIABETES RESEARCH AND CLINICAL PRACTICE